Liver-cancer patients gain time before progression; survival remains unresolved

Oncology · Source date: November 2026 journal issue; indexed by November 2 · Evidence: Randomized phase 3 trial; overall survival immature · Primary source

For patients with unresectable hepatocellular carcinoma, transarterial chemoembolization (TACE) can contain disease but frequently loses effectiveness. The TALENTACE study asked whether combining on-demand TACE with atezolizumab and bevacizumab would extend the period before disease became untreatable by TACE or the patient died. It randomized 342 people across 40 centers in China and Japan, with preserved liver function and a substantial tumor burden.

Median TACE progression-free survival improved from 7.03 to 11.30 months (hazard ratio 0.71; 95% CI 0.55–0.92). The difference did not translate into a demonstrated overall-survival advantage at the first planned interim analysis: median survival was 34.53 versus 35.38 months, with highly uncertain estimates. Treatment-related deaths were reported in five participants in the combination arm and three in TACE alone. Patients were selected for Child-Pugh A liver function, which limits generalization to the more medically fragile populations encountered in practice.

Longer disease control may come with additional treatment and monitoring. Progression-free survival and overall survival are distinct outcomes. Shanghai Roche Pharmaceuticals sponsored the study.

regulatory/guideline context; OS not established.